DK0651739T3 - Hydroxamsyrederivater som metallo-proteinase-inhibitorer - Google Patents

Hydroxamsyrederivater som metallo-proteinase-inhibitorer

Info

Publication number: DK0651739T3
Authority: DK; Denmark
Prior art keywords: metalloproteinase inhibitors; acid derivatives; hydroxamic acid; substituted phenyl; hydrogen
Prior art date: 1992-07-23

Application number

DK93917901.6T

Other languages

English (en)

Inventor

Jonathon Philip Dickens

Michael John Crimmin

Raymond Paul Beckett

Original Assignee

British Biotech Pharm

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-07-23

Filing date

1993-07-23

Publication date

1997-08-18

1993-07-23 Application filed by British Biotech Pharm filed Critical British Biotech Pharm

1997-08-18 Application granted granted Critical

1997-08-18 Publication of DK0651739T3 publication Critical patent/DK0651739T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Nutrition Science (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Adhesives Or Adhesive Processes (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

DK93917901.6T 1992-07-23 1993-07-23 Hydroxamsyrederivater som metallo-proteinase-inhibitorer DK0651739T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB929215665A GB9215665D0 (en)	1992-07-23	1992-07-23	Compounds

Publications (1)

Publication Number	Publication Date
DK0651739T3 true DK0651739T3 (da)	1997-08-18

Family

ID=10719178

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK96115235T DK0754688T3 (da)	1992-07-23	1993-07-23	Dioxolanmellemprodukter
DK93917901.6T DK0651739T3 (da)	1992-07-23	1993-07-23	Hydroxamsyrederivater som metallo-proteinase-inhibitorer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK96115235T DK0754688T3 (da)	1992-07-23	1993-07-23	Dioxolanmellemprodukter

Country Status (26)

Country	Link
US (3)	US5643964A (da)
EP (3)	EP0754688B1 (da)
JP (3)	JPH07509459A (da)
KR (1)	KR100205710B1 (da)
AT (3)	ATE151414T1 (da)
AU (2)	AU661410B2 (da)
CA (1)	CA2140626C (da)
CY (1)	CY1944A (da)
CZ (1)	CZ285896B6 (da)
DE (5)	DE69316367T2 (da)
DK (2)	DK0754688T3 (da)
ES (1)	ES2153927T3 (da)
FI (1)	FI114549B (da)
GB (4)	GB9215665D0 (da)
GR (2)	GR3023522T3 (da)
HK (1)	HK149396A (da)
HU (2)	HU220625B1 (da)
NO (1)	NO303221B1 (da)
NZ (1)	NZ254862A (da)
PL (1)	PL174279B1 (da)
PT (1)	PT754688E (da)
RU (1)	RU2126791C1 (da)
SK (1)	SK281240B6 (da)
UA (1)	UA29450C2 (da)
WO (2)	WO1994002447A1 (da)
ZA (2)	ZA935351B (da)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9307956D0 (en) *	1993-04-17	1993-06-02	Walls Alan J	Hydroxamic acid derivatives
ES2075797B1 (es) *	1993-08-18	1996-05-16	British Bio Technology	Derivados de acidos hidroxamicos terapeuticamente activos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de dichos compuestos en medicina.
ES2075798B1 (es) *	1993-08-18	1996-03-01	British Bio Technology	Derivados de aminoacidos naturales como inhibidores de metaloproteinasas, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de dichos compuestos en medicina.
US5594106A (en) *	1993-08-23	1997-01-14	Immunex Corporation	Inhibitors of TNF-α secretion
FI960803L (fi) *	1993-08-23	1996-04-22	Immunex Corp	TNF-alfa-sekreetion inhibiittoreita
GB2299335B (en) *	1994-01-21	1997-12-17	British Biotech Pharm	Hydroxamic acid derivatives as metalloproteinase inhibitors
GB9401129D0 (en) *	1994-01-21	1994-03-16	British Bio Technology	Hydroxamic acid derivatives as metalloproteinase inhibitors
DE69512891T2 (de) *	1994-01-22	2000-02-24	British Biotech Pharmaceuticals Ltd., Cowley	Metalloproteinaseinhibitoren
GB9404046D0 (en) *	1994-03-03	1994-04-20	Smithkline Beecham Corp	Novel compounds
GB9411088D0 (en) *	1994-06-03	1994-07-27	Hoffmann La Roche	Hydroxylamine derivatives
GB9416897D0 (en) *	1994-08-20	1994-10-12	British Biotech Pharm	Metalloproteinase inhibitors
GB9423914D0 (en) *	1994-11-26	1995-01-11	British Biotech Pharm	Polyether derivatives as metalloproteinase inhibitors
US5639746A (en) *	1994-12-29	1997-06-17	The Procter & Gamble Company	Hydroxamic acid-containing inhibitors of matrix metalloproteases
US5672598A (en) *	1995-03-21	1997-09-30	The Procter & Gamble Company	Lactam-containing hydroxamic acids
AU5002196A (en) *	1995-03-28	1996-10-16	Novo Nordisk A/S	Immunosuppressive agents
GB9507799D0 (en) *	1995-04-18	1995-05-31	British Biotech Pharm	Metalloproteinase inhibitors
US5691381A (en) *	1995-04-18	1997-11-25	The Dupont Merck Pharmaceutical Company	Hydroxamic and carbocyclic acids as metalloprotease inhibitors
JP3156794B2 (ja)	1995-04-25	2001-04-16	富士薬品工業株式会社	高水溶性メタロプロテイナーゼ阻害剤
CA2219973A1 (en) *	1995-05-10	1996-11-14	Chiroscience Limited	Peptidyl compounds and their therapeutic use
GB9513331D0 (en) *	1995-06-30	1995-09-06	British Biotech Pharm	Matrix metalloproteinase inhibitors
US5917090A (en) *	1995-06-30	1999-06-29	British Biotech Pharmaceuticals Ltd.	Matrix metalloproteinase inhibitors
WO1997003966A1 (en) *	1995-07-19	1997-02-06	British Biotech Pharmaceuticals Limited	N-(amino acid) substituted succinic acid amide derivatives as metalloproteinase inhibitors
GB9514867D0 (en) *	1995-07-20	1995-09-20	British Biotech Pharm	Metalloproteinase inhibitors
GB2318353B (en) *	1995-07-20	1999-10-06	British Biotech Pharm	Metalloproteinase inhibitors
US6281352B1 (en)	1995-11-14	2001-08-28	Dupont Pharmaceuticals Company	Macrocyclic compounds as metalloprotease inhibitors
GB9523637D0 (en) *	1995-11-18	1996-01-17	British Biotech Pharm	Synthesis of carboxylic acid derivatives
AU711907B2 (en) *	1995-11-22	1999-10-21	Darwin Discovery Limited	Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (MMP) and/or tumor necrosis factor (TNF)
ATE205184T1 (de)	1995-11-23	2001-09-15	British Biotech Pharm	Metalloproteinase inhibitoren
GB9609702D0 (en)	1996-05-09	1996-07-10	Royal Free Hosp School Med	Anticoagulant peptides
GB9609794D0 (en) *	1996-05-10	1996-07-17	Smithkline Beecham Plc	Novel compounds
JP3347331B2 (ja) *	1996-08-28	2002-11-20	ザプロクターアンドギャンブルカンパニー	複素環式メタロプロテアーゼ阻害剤
PL331838A1 (en) *	1996-08-28	1999-08-02	Procter & Gamble	1,3-diheterocyclic inhibitors of metaloproteases
CA2264254C (en) *	1996-08-28	2003-03-11	Yetunde Olabisi Taiwo	Phosphinic acid amides as matrix metalloprotease inhibitors
IL128662A0 (en) *	1996-08-28	2000-01-31	Procter & Gamble	Heterocyclic metalloprotease inhibitors
TR199900429T2 (xx) *	1996-08-28	1999-05-21	The Procter & Gamble Company	Spirosiklik metaloproteaz inhibit�rleri.
US6462023B1 (en)	1996-09-10	2002-10-08	British Biotech Pharmaceuticals, Ltd.	Cytostatic agents
CN1230175A (zh)	1996-09-10	1999-09-29	英国生物技术药物有限公司	有细胞抑制作用的羟肟酸衍生物
GB9708265D0 (en) *	1997-04-24	1997-06-18	Nycomed Imaging As	Contrast agents
US5985911A (en) *	1997-01-07	1999-11-16	Abbott Laboratories	C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US5952320A (en) *	1997-01-07	1999-09-14	Abbott Laboratories	Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US6242615B1 (en)	1997-03-28	2001-06-05	Zeneca Limited	Process for the preparation of N-(3-hydroxy-succinyl)-amino acid derivatives
WO1998043959A1 (en) *	1997-03-28	1998-10-08	Zeneca Limited	Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor
US5883131A (en) *	1997-07-09	1999-03-16	Pfizer Inc.	Cyclic sulfone derivatives
AU746877B2 (en)	1997-07-31	2002-05-02	Procter & Gamble Company, The	Acyclic metalloprotease inhibitors
HRP980443A2 (en)	1997-08-18	1999-10-31	Carl P. Decicco	Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
EP0897908A1 (de) *	1997-08-19	1999-02-24	Roche Diagnostics GmbH	3-Aryl-Succinamido-Hydroxamsäuren, Prozesse zu ihrer Herstellung und diese Substanzen enthaltende Medikamente
US6403632B1 (en)	2000-03-01	2002-06-11	Bristol Myers Squibb Pharma Co	Lactam metalloprotease inhibitors
ZA988967B (en) *	1997-10-03	2000-04-03	Du Pont Pharm Co	Lactam metalloprotease inhibitors.
NZ503637A (en) *	1997-10-06	2002-10-25	American Cyanamid Co	Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids and their use as matrix metalloproteinase and TACE inhibitors
US6420427B1 (en) *	1997-10-09	2002-07-16	Ono Pharmaceutical Co., Ltd.	Aminobutyric acid derivatives
CA2310031C (en) †	1997-11-14	2005-03-29	Donald Carroll Roe	Disposable absorbent article with a skin care composition on an apertured top sheet
EA002971B1 (ru)	1998-01-09	2002-12-26	Пфайзер Инк.	Ингибиторы металлопротеаз матрикса, способы их получения, фармкомпозиция, применение и способ лечения
AU2594799A (en)	1998-02-11	1999-08-30	Du Pont Pharmaceuticals Company	Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
AU747977B2 (en) *	1998-03-12	2002-05-30	British Biotech Pharmaceuticals Limited	Cytostatic agents
US6329418B1 (en)	1998-04-14	2001-12-11	The Procter & Gamble Company	Substituted pyrrolidine hydroxamate metalloprotease inhibitors
EP1155092A1 (en)	1998-10-21	2001-11-21	W.R. Grace & Co.-Conn.	Slurries of abrasive inorganic oxide particles and method for adjusting the abrasiveness of the particles
US6447693B1 (en)	1998-10-21	2002-09-10	W. R. Grace & Co.-Conn.	Slurries of abrasive inorganic oxide particles and method for polishing copper containing surfaces
US6288261B1 (en)	1998-12-18	2001-09-11	Abbott Laboratories	Inhibitors of matrix metalloproteinases
NZ513831A (en)	1999-03-03	2001-09-28	Procter & Gamble	Alkenyl- and alkynyl-containing metalloprotease inhibitors
CA2361848A1 (en)	1999-04-02	2000-10-12	Dupont Pharmaceuticals Company	Novel lactam inhibitors of matrix metalloproteinases, tnf-.alpha., and aggrecanase
EP1165500A1 (en)	1999-04-02	2002-01-02	Du Pont Pharmaceuticals Company	Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase
US20040220103A1 (en)	1999-04-19	2004-11-04	Immunex Corporation	Soluble tumor necrosis factor receptor treatment of medical disorders
US6297337B1 (en)	1999-05-19	2001-10-02	Pmd Holdings Corp.	Bioadhesive polymer compositions
JP2001055327A (ja) *	1999-06-11	2001-02-27	Fuji Chemical Industries Ltd	新規なヒドロキサム酸誘導体を含む医薬
US6696456B1 (en)	1999-10-14	2004-02-24	The Procter & Gamble Company	Beta disubstituted metalloprotease inhibitors
GB9929527D0 (en) *	1999-12-14	2000-02-09	Smithkline Beecham Plc	Novel compounds
US6797820B2 (en) *	1999-12-17	2004-09-28	Vicuron Pharmaceuticals Inc.	Succinate compounds, compositions and methods of use and preparation
RU2189206C2 (ru) *	2000-02-04	2002-09-20	Ченцова Екатерина Валериановна	Способ лечения дефектов роговицы
US7141607B1 (en)	2000-03-10	2006-11-28	Insite Vision Incorporated	Methods and compositions for treating and inhibiting retinal neovascularization
SK12842002A3 (sk)	2000-03-21	2003-02-04	The Procter And Gamble Company	Heterocyklický vedľajší reťazec obsahujúci N-substituované inhibítory metaloproteáz a farmaceutický prípravok s ich obsahom
IL151250A0 (en)	2000-03-21	2003-04-10	Procter & Gamble	Difluorobutyric acid metalloprotease inhibitors
US6620823B2 (en)	2000-07-11	2003-09-16	Bristol-Myers Squibb Pharme Company	Lactam metalloprotease inhibitors
PE20020354A1 (es) *	2000-09-01	2002-06-12	Novartis Ag	Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
ATE360014T1 (de)	2001-06-15	2007-05-15	Vicuron Pharm Inc	Bicyclische pyrrolidinverbindungen
AR036053A1 (es)	2001-06-15	2004-08-04	Versicor Inc	Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
PE20030701A1 (es)	2001-12-20	2003-08-21	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
EP2316468A1 (en)	2002-02-22	2011-05-04	Shire LLC	Delivery system and methods for protecting and administering dextroamphetamine
JP2006516548A (ja)	2002-12-30	2006-07-06	アンジオテックインターナショナルアクツィエンゲゼルシャフト	迅速ゲル化ポリマー組成物からの薬物送達法
BRPI0407587A (pt) *	2003-02-18	2006-02-14	Pfizer	inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
WO2004101523A1 (en)	2003-05-17	2004-11-25	Korea Research Institute Of Bioscience And Biotechnology	Novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same
JP4901474B2 (ja)	2003-05-30	2012-03-21	ランバクシーラボラトリーズリミテッド	置換ピロール誘導体
WO2005014825A2 (en)	2003-08-08	2005-02-17	Arriva Pharmaceuticals, Inc.	Methods of protein production in yeast
PL379887A1 (pl) *	2003-08-26	2006-11-27	Merck Hdac Research, Llc	Sposób leczenia raka inhibitorami HDAC
JP2007528409A (ja)	2004-03-09	2007-10-11	アリバファーマシューティカルズ，インコーポレイテッド	プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置
RS50980B (sr)	2004-07-26	2010-10-31	Merck Serono Sa.	Derivati n-hidroksiamida i njihova upotreba
DE102005021806A1 (de) *	2005-05-04	2006-11-16	Lancaster Group Gmbh	Verwendung von radikalfangenden Substanzen zur Behandlung von Zuständen mit erhöhter Hauttemperatur, insbesondere zur antipyretischen Behandlung
ATE518853T1 (de)	2005-08-12	2011-08-15	Schering Corp	Verbindungen zur behandlung entzündlicher erkrankungen
KR101329112B1 (ko)	2005-11-08	2013-11-14	랜박시 래보러터리스 리미티드	(3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
DE102007027772A1 (de) *	2007-06-16	2008-12-24	Ab Skf	Anodnung zur Lagerung eines Maschinenteils
DE102007062199A1 (de) *	2007-12-21	2009-06-25	Evonik Degussa Gmbh	2-Methylthioethyl-substituierte Heterocyclen als Futtermitteladditive
IT1401253B1 (it)	2010-04-23	2013-07-18	Uni Degli Studi Carlo Bo Urbino	Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
FR3010076B1 (fr) *	2013-09-02	2016-12-23	Centre Nat De La Rech Scient - Cnrs -	Inhibiteurs de metalloproteases, leurs procedes de preparation et leurs utilisations therapeutiques
WO2015107139A1 (en) *	2014-01-17	2015-07-23	Proyecto De Biomedicina Cima, S.L.	Compounds for use as antifibrinolytic agents
EP3860608A1 (en)	2018-10-04	2021-08-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Egfr inhibitors for treating keratodermas
IT202100023357A1 (it)	2021-09-09	2023-03-09	Cheirontech S R L	Peptidi con attività anti-angiogenica
PL447395A1 (pl)	2023-12-29	2025-06-30	Pikralida Spółka Z Ograniczoną Odpowiedzialnością	Sposób wytwarzania marimastatu, marimastat wytworzony tym sposobem, zawierająca go kompozycja farmaceutyczna oraz ich zastosowania
PL447396A1 (pl)	2023-12-29	2025-06-30	Pikralida Spółka Z Ograniczoną Odpowiedzialnością	Krystaliczne formy polimorficzne marimastatu, postać amorficzna marimastatu, sposoby ich wytwarzania, zawierające je kompozycje farmaceutyczne oraz ich zastosowania

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL122359C (da) *	1964-03-06
IT1201443B (it) *	1985-07-31	1989-02-02	Zambon Spa	Intermedi per la sintesi di acidi carbossilici
US4599361A (en) *	1985-09-10	1986-07-08	G. D. Searle & Co.	Hydroxamic acid based collagenase inhibitors
DK77487A (da) *	1986-03-11	1987-09-12	Hoffmann La Roche	Hydroxylaminderivater
IT1198237B (it) *	1986-12-23	1988-12-21	Zambon Spa	Intermedi per la sintesi di composti organici
FR2609289B1 (fr) *	1987-01-06	1991-03-29	Bellon Labor Sa Roger	Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
GB8827305D0 (en) *	1988-11-23	1988-12-29	British Bio Technology	Compounds
GB8827308D0 (en) *	1988-11-23	1988-12-29	British Bio Technology	Compounds
GB8919251D0 (en) *	1989-08-24	1989-10-04	British Bio Technology	Compounds
US5183900A (en) *	1990-11-21	1993-02-02	Galardy Richard E	Matrix metalloprotease inhibitors
DE69108363T2 (de) *	1990-12-03	1995-08-31	Celltech Ltd	Peptidylderivate.
CA2058797A1 (en) *	1991-02-01	1992-08-02	Michael John Broadhurst	Amino acid derivatives
GB9102635D0 (en) *	1991-02-07	1991-03-27	British Bio Technology	Compounds
JPH05125029A (ja) *	1991-11-06	1993-05-21	Yamanouchi Pharmaceut Co Ltd	新規なアミド化合物又はその塩
GB9307956D0 (en) *	1993-04-17	1993-06-02	Walls Alan J	Hydroxamic acid derivatives

1992
- 1992-07-23 GB GB929215665A patent/GB9215665D0/en active Pending
1993
- 1993-07-22 GB GB9500722A patent/GB2287023B/en not_active Expired - Fee Related
- 1993-07-22 GB GB9315222A patent/GB2268934B/en not_active Expired - Fee Related
- 1993-07-22 GB GB9315206A patent/GB2268933B/en not_active Expired - Fee Related
- 1993-07-23 AT AT93917901T patent/ATE151414T1/de not_active IP Right Cessation
- 1993-07-23 CZ CZ95157A patent/CZ285896B6/cs not_active IP Right Cessation
- 1993-07-23 EP EP96115235A patent/EP0754688B1/en not_active Expired - Lifetime
- 1993-07-23 US US08/374,601 patent/US5643964A/en not_active Expired - Fee Related
- 1993-07-23 AU AU47153/93A patent/AU661410B2/en not_active Ceased
- 1993-07-23 DE DE69316367T patent/DE69316367T2/de not_active Expired - Fee Related
- 1993-07-23 EP EP93917900A patent/EP0651738B1/en not_active Expired - Lifetime
- 1993-07-23 DK DK96115235T patent/DK0754688T3/da active
- 1993-07-23 US US08/374,602 patent/US5700838A/en not_active Expired - Fee Related
- 1993-07-23 SK SK78-95A patent/SK281240B6/sk unknown
- 1993-07-23 RU RU95109920/04A patent/RU2126791C1/ru not_active IP Right Cessation
- 1993-07-23 PT PT96115235T patent/PT754688E/pt unknown
- 1993-07-23 WO PCT/GB1993/001557 patent/WO1994002447A1/en not_active Ceased
- 1993-07-23 DK DK93917901.6T patent/DK0651739T3/da active
- 1993-07-23 DE DE69309686T patent/DE69309686T2/de not_active Expired - Fee Related
- 1993-07-23 ES ES96115235T patent/ES2153927T3/es not_active Expired - Lifetime
- 1993-07-23 UA UA95018066A patent/UA29450C2/uk unknown
- 1993-07-23 ZA ZA935351A patent/ZA935351B/xx unknown
- 1993-07-23 JP JP6504306A patent/JPH07509459A/ja active Pending
- 1993-07-23 EP EP93917901A patent/EP0651739B1/en not_active Expired - Lifetime
- 1993-07-23 ZA ZA935352A patent/ZA935352B/xx unknown
- 1993-07-23 DE DE9321495U patent/DE9321495U1/de not_active Expired - Lifetime
- 1993-07-23 PL PL93307171A patent/PL174279B1/pl not_active IP Right Cessation
- 1993-07-23 AU AU47152/93A patent/AU4715293A/en not_active Abandoned
- 1993-07-23 AT AT93917900T patent/ATE162183T1/de active
- 1993-07-23 HU HU9500202A patent/HU220625B1/hu not_active IP Right Cessation
- 1993-07-23 KR KR1019950700232A patent/KR100205710B1/ko not_active Expired - Fee Related
- 1993-07-23 DE DE69329804T patent/DE69329804T2/de not_active Expired - Fee Related
- 1993-07-23 JP JP6504307A patent/JP2768554B2/ja not_active Expired - Fee Related
- 1993-07-23 WO PCT/GB1993/001556 patent/WO1994002446A1/en not_active Ceased
- 1993-07-23 NZ NZ254862A patent/NZ254862A/en not_active IP Right Cessation
- 1993-07-23 DE DE4393452T patent/DE4393452T1/de not_active Ceased
- 1993-07-23 CA CA002140626A patent/CA2140626C/en not_active Expired - Fee Related
- 1993-07-23 AT AT96115235T patent/ATE198331T1/de not_active IP Right Cessation
1995
- 1995-01-20 NO NO950226A patent/NO303221B1/no unknown
- 1995-01-20 FI FI950262A patent/FI114549B/fi not_active IP Right Cessation
- 1995-06-12 HU HU95P/P00187P patent/HU211287A9/hu unknown
1996
- 1996-08-08 HK HK149396A patent/HK149396A/xx not_active IP Right Cessation
1997
- 1997-05-16 CY CY194497A patent/CY1944A/en unknown
- 1997-05-23 GR GR970401170T patent/GR3023522T3/el unknown
- 1997-10-23 US US08/956,338 patent/US5912360A/en not_active Expired - Lifetime
- 1997-12-22 JP JP9353810A patent/JP2971053B2/ja not_active Expired - Fee Related
2001
- 2001-03-05 GR GR20010400350T patent/GR3035510T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE9321495U1 (de)	1998-09-10
GB2287023B (en)	1996-02-14
SK7895A3 (en)	1995-07-11
EP0754688A3 (en)	1997-07-30
GR3035510T3 (en)	2001-06-29
ATE198331T1 (de)	2001-01-15
NO950226D0 (no)	1995-01-20
FI950262A0 (fi)	1995-01-20
DE69309686T2 (de)	1997-07-24
WO1994002446A1 (en)	1994-02-03
AU4715293A (en)	1994-02-14
ATE151414T1 (de)	1997-04-15
EP0651739A1 (en)	1995-05-10
CZ285896B6 (cs)	1999-11-17
GR3023522T3 (en)	1997-08-29
DK0754688T3 (da)	2001-03-05
DE69329804D1 (de)	2001-02-01
PL174279B1 (pl)	1998-07-31
HUT70552A (en)	1995-10-30
DE69309686D1 (de)	1997-05-15
GB2268934A (en)	1994-01-26
HU9500202D0 (en)	1995-03-28
NZ254862A (en)	1996-02-27
KR950702525A (ko)	1995-07-29
CY1944A (en)	1997-05-16
EP0754688B1 (en)	2000-12-27
AU661410B2 (en)	1995-07-20
EP0651738B1 (en)	1998-01-14
CZ15795A3 (en)	1995-10-18
ZA935352B (en)	1994-05-16
HK149396A (en)	1996-08-16
KR100205710B1 (ko)	1999-07-01
EP0651739B1 (en)	1997-04-09
GB9315206D0 (en)	1993-09-08
WO1994002447A1 (en)	1994-02-03
GB2287023A (en)	1995-09-06
ES2153927T3 (es)	2001-03-16
HU211287A9 (en)	1995-11-28
UA29450C2 (uk)	2000-11-15
DE69329804T2 (de)	2001-05-31
US5912360A (en)	1999-06-15
PT754688E (pt)	2001-04-30
EP0754688A2 (en)	1997-01-22
DE69316367D1 (de)	1998-02-19
AU4715393A (en)	1994-02-14
GB2268933A (en)	1994-01-26
GB9500722D0 (en)	1995-03-08
EP0651738A1 (en)	1995-05-10
JPH10204081A (ja)	1998-08-04
FI950262A7 (fi)	1995-01-20
FI114549B (fi)	2004-11-15
JP2768554B2 (ja)	1998-06-25
JPH07509460A (ja)	1995-10-19
CA2140626A1 (en)	1994-02-03
CA2140626C (en)	2002-09-03
NO950226L (no)	1995-01-20
RU95109920A (ru)	1996-10-27
NO303221B1 (no)	1998-06-15
JP2971053B2 (ja)	1999-11-02
HU220625B1 (hu)	2002-03-28
JPH07509459A (ja)	1995-10-19
PL307171A1 (en)	1995-05-15
GB2268933B (en)	1996-04-10
US5700838A (en)	1997-12-23
ZA935351B (en)	1994-02-14
ATE162183T1 (de)	1998-01-15
GB9215665D0 (en)	1992-09-09
US5643964A (en)	1997-07-01
GB2268934B (en)	1996-01-24
SK281240B6 (sk)	2001-01-18
DE4393452T1 (de)	1995-06-01
DE69316367T2 (de)	1998-06-10
GB9315222D0 (en)	1993-09-08
RU2126791C1 (ru)	1999-02-27

Publication	Publication Date	Title
DK0651739T3 (da)	1997-08-18	Hydroxamsyrederivater som metallo-proteinase-inhibitorer
NL300215I1 (nl)	2006-03-01	Depsipeptide-derivaat, productie daarvan en toepassing daarvan.
DK0906907T3 (da)	2002-04-22	Forbindelser, der potenserer retinoid
DK1300401T3 (da)	2010-02-01	Thiazolderivater til anvendelse som antiinflammatoriske midler
ES2046229T3 (es)	1994-02-01	Composicion antiulcerosa.
ATE115545T1 (de)	1994-12-15	Aralkylamin-verbindungen.
ATE222246T1 (de)	2002-08-15	Benzoamid-derivat, antiulcus und antibakterielle mittel
NO175253C (no)	1994-09-21	Forbindelse, anvendelse og preparat
DK0413278T3 (da)	1997-04-07	Anvendelse af xanthinderivater mod mavesår
ATE117671T1 (de)	1995-02-15	Aminoketonverbindungen.
ES8303381A1 (es)	1983-02-01	Procedimiento para la fabricacion de un compuesto de fenil- 1,3-perhidrotiacina-4-ona, 2-substituida
FI900796A0 (fi)	1990-02-16	Aralkylaminfoereningar.